After WBRT, what systemic therapy would you favor for maximal CNS penetrance in a patient with triple negative metastatic breast cancer and multifocal CNS disease?
Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?
Community PollStarted
Which systemic therapy do you feel maximizes CNS penetrance for triple negative breast cancer?
38 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Rochester
Answered on
With patients such as this, I would usually recommend the following:
1. Genomic testing (Strata, Foundation 1, etc.) to look for a mutation that might be targetable with a TKI that crosses the blood brain barrier well
2. Re-testing of the CNS cytology for HER2, given that we do have multiple drugs w...
Join for free or sign in to see the full answer